PETER P. BRADLEY, M.D.; GLEN D. WARDEN, M.D.; JOHN G. MAXWELL, M.D.; GERALD ROTHSTEIN, M.D.
▸Requests for reprints should be addressed to Peter P. Bradley, M.D.; Division of Hematology/Oncology, University of Utah Medical Center, 50 North Medical Drive; Salt Lake City, UT 84132.
BRADLEY P., WARDEN G., MAXWELL J., ROTHSTEIN G.; Neutropenia and Thrombocytopenia in Renal Allograft Recipients Treated with Trimethoprim-Sulfamethoxazole. Ann Intern Med. 1980;93:560-562. doi: 10.7326/0003-4819-93-4-560
Download citation file:
Published: Ann Intern Med. 1980;93(4):560-562.
Hematologic toxicity occurred when trimethoprim-sulfamethoxazole was given for prolonged periods to renal allograft subjects also treated with azathioprine. In six such patients, the incidences and duration of neutropenia and thrombocytopenia were greater than in 25 similar allograft recipients treated with azathioprine alone. In bone marrow culture, the antifolate action of trimethoprim-sulfamethoxazole enhanced the marrow-suppressive effect of 6-mercaptopurine, the active moiety cleaved from azathioprine. These studies show that in renal allograft recipients treated with azathioprine, the prolonged use of trimethoprim-sulfamethoxazole may result in life-threatening hematotoxicity.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Hematology/Oncology, Nephrology, Platelet Disorders.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only